O	0	1	[
O	1	9	Interest
O	10	12	of
O	13	14	a
B-intervention	15	23	thrombin
I-intervention	24	27	and
I-intervention	28	38	fibrinogen
I-intervention	39	49	combipatch
O	50	52	in
O	53	63	preventing
O	64	70	breast
O	71	77	cancer
B-condition	78	84	seroma
O	85	90	after
O	91	96	lymph
O	97	101	node
O	102	112	dissection
O	112	113	]
O	113	114	.

O	115	117	To
O	118	126	evaluate
O	127	130	the
O	131	137	effect
O	138	140	of
O	141	151	combipatch
O	152	160	TachoSil
O	160	161	(
O	161	162	®
O	162	163	)
O	164	166	in
O	167	170	the
O	171	181	prevention
O	182	184	of
O	185	192	seromas
O	193	198	after
O	199	207	axillary
O	208	218	dissection
O	219	221	in
O	222	227	local
O	228	234	breast
O	235	241	cancer
O	241	242	.

O	243	251	PATIENTS
O	252	254	ET
O	255	256	M
O	256	257	É
O	257	263	THODES
O	263	264	:
O	265	266	A
O	267	280	retrospective
O	280	281	,
O	282	286	case
O	286	287	-
O	287	294	control
O	295	300	study
O	301	310	conducted
O	311	318	between
O	319	326	January
O	327	331	2007
O	332	335	and
O	336	344	December
O	345	349	2009
O	349	350	,
O	351	353	in
O	354	357	two
O	358	369	departments
O	370	372	of
O	373	383	Obstetrics
O	384	387	and
O	388	398	Gynecology
O	399	401	of
O	402	405	the
O	406	408	AP
O	408	409	-
O	409	411	HP
O	411	412	.

B-total-participants	413	418	Sixty
I-total-participants	418	419	-
I-total-participants	419	422	six
O	423	431	patients
O	432	433	(
B-control-participants	433	435	45
O	436	438	in
O	439	442	the
B-control	443	450	control
I-control	451	456	group
O	457	460	and
B-intervention-participants	461	463	22
O	464	466	in
O	467	470	the
O	471	476	group
O	477	485	TachoSil
O	485	486	(
O	486	487	®
O	487	488	)
O	488	489	)
B-eligibility	490	493	who
I-eligibility	494	498	have
I-eligibility	499	508	undergone
I-eligibility	509	511	an
I-eligibility	512	520	axillary
I-eligibility	521	531	dissection
I-eligibility	532	537	alone
I-eligibility	537	538	,
I-eligibility	539	543	with
I-eligibility	544	557	establishment
I-eligibility	558	560	of
I-eligibility	561	562	a
I-eligibility	563	568	redon
I-eligibility	569	571	or
I-eligibility	572	576	with
I-eligibility	577	587	lumpectomy
O	587	588	,
O	589	593	were
O	594	602	included
O	602	603	.

O	604	607	The
O	608	613	total
O	614	620	amount
O	621	623	of
O	624	629	lymph
O	630	637	drained
O	638	644	during
O	645	648	the
O	649	653	stay
O	653	654	,
O	655	658	the
O	659	665	number
O	666	668	of
O	669	673	days
O	674	676	of
O	677	685	drainage
O	685	686	,
O	687	695	duration
O	696	698	of
O	699	714	hospitalization
O	714	715	,
O	716	719	the
O	720	726	number
O	727	729	of
O	730	741	lymphoceles
O	742	745	and
O	746	749	the
O	750	756	number
O	757	759	of
O	760	770	retrievals
O	771	780	performed
O	781	783	at
O	784	787	the
O	788	794	waning
O	795	797	of
O	798	813	hospitalization
O	814	818	were
O	819	828	collected
O	828	829	.

O	830	833	The
O	834	844	population
O	845	848	was
O	849	856	similar
O	857	859	in
O	860	863	age
O	863	864	,
O	865	869	body
O	870	874	mass
O	875	880	index
O	881	882	(
O	882	885	BMI
O	885	886	)
O	886	887	,
O	888	896	clinical
O	897	900	and
O	901	913	pathological
O	914	918	data
O	918	919	.

O	920	925	There
O	926	929	was
O	930	932	no
O	933	944	significant
O	945	955	difference
O	956	958	in
O	959	964	terms
O	965	967	of
B-outcome	968	973	total
I-outcome	974	980	volume
I-outcome	981	983	of
I-outcome	984	989	lymph
I-outcome	990	997	drained
O	998	999	(
B-cv-cont-mean	999	1002	268
I-cv-cont-mean	1002	1003	.
I-cv-cont-mean	1003	1004	2
O	1005	1006	±
B-cv-cont-sd	1007	1010	220
I-cv-cont-sd	1010	1011	.
I-cv-cont-sd	1011	1012	7
I-cv-cont-sd	1013	1015	mL
O	1016	1023	without
O	1024	1032	TachoSil
O	1032	1033	(
O	1033	1034	®
O	1034	1035	)
O	1036	1039	and
B-iv-cont-mean	1040	1043	228
I-iv-cont-mean	1043	1044	.
I-iv-cont-mean	1044	1045	6
O	1046	1047	±
B-iv-cont-sd	1048	1051	128
I-iv-cont-sd	1051	1052	.
I-iv-cont-sd	1052	1053	8
I-iv-cont-sd	1054	1056	mL
O	1057	1061	with
O	1062	1070	TachoSil
O	1070	1071	(
O	1071	1072	®
O	1072	1073	)
O	1073	1074	,
O	1075	1076	P
O	1077	1078	=
O	1079	1080	0
O	1080	1081	.
O	1081	1083	89
O	1083	1084	)
O	1085	1088	and
O	1089	1092	the
B-outcome	1093	1099	number
I-outcome	1100	1102	of
I-outcome	1103	1107	days
I-outcome	1108	1110	of
I-outcome	1111	1119	drainage
O	1120	1121	(
B-cv-cont-mean	1121	1122	3
I-cv-cont-mean	1122	1123	.
I-cv-cont-mean	1123	1124	9
O	1125	1126	±
B-cv-cont-sd	1127	1128	1
I-cv-cont-sd	1128	1129	.
I-cv-cont-sd	1129	1130	6
I-cv-cont-sd	1131	1135	days
O	1136	1143	without
O	1144	1152	TachoSil
O	1152	1153	(
O	1153	1154	®
O	1154	1155	)
O	1156	1159	and
B-iv-cont-mean	1160	1161	3
I-iv-cont-mean	1161	1162	.
I-iv-cont-mean	1162	1163	1
O	1164	1165	±
B-iv-cont-sd	1166	1167	0
I-iv-cont-sd	1167	1168	.
I-iv-cont-sd	1168	1169	9
I-iv-cont-sd	1170	1174	days
O	1175	1179	with
O	1180	1188	TachoSil
O	1188	1189	(
O	1189	1190	®
O	1190	1191	)
O	1191	1192	,
O	1193	1194	P
O	1195	1196	=
O	1197	1198	0
O	1198	1199	.
O	1199	1201	10
O	1201	1202	)
O	1202	1203	.

O	1204	1207	The
B-outcome	1208	1216	duration
I-outcome	1217	1219	of
I-outcome	1220	1235	hospitalization
O	1236	1239	was
O	1240	1253	significantly
O	1254	1260	higher
O	1261	1263	in
O	1264	1267	the
O	1268	1273	group
O	1274	1282	TachoSil
O	1282	1283	(
O	1283	1284	®
O	1284	1285	)
O	1286	1287	(
B-iv-cont-mean	1287	1288	5
O	1289	1290	±
B-iv-cont-sd	1291	1292	1
I-iv-cont-sd	1292	1293	.
I-iv-cont-sd	1293	1294	6
I-iv-cont-sd	1295	1299	days
O	1300	1304	with
O	1305	1313	TachoSil
O	1313	1314	(
O	1314	1315	®
O	1315	1316	)
O	1317	1320	and
B-cv-cont-mean	1321	1322	3
I-cv-cont-mean	1322	1323	.
I-cv-cont-mean	1323	1324	8
O	1325	1326	±
B-cv-cont-sd	1327	1328	1
I-cv-cont-sd	1328	1329	.
I-cv-cont-sd	1329	1330	1
I-cv-cont-sd	1331	1335	days
O	1336	1343	without
O	1344	1352	TachoSil
O	1352	1353	(
O	1353	1354	®
O	1354	1355	)
O	1355	1356	,
O	1357	1358	P
O	1359	1360	=
O	1361	1362	0
O	1362	1363	.
O	1363	1366	006
O	1366	1367	)
O	1367	1368	.

O	1369	1373	This
O	1374	1379	study
O	1380	1385	shows
O	1386	1388	no
O	1389	1396	benefit
O	1397	1399	of
O	1400	1410	combipatch
O	1411	1412	(
O	1412	1420	TachoSil
O	1420	1421	(
O	1421	1422	®
O	1422	1423	)
O	1423	1424	)
O	1425	1427	in
O	1428	1438	prevention
O	1439	1441	of
O	1442	1449	seromas
O	1450	1455	after
O	1456	1464	axillary
O	1465	1470	lymph
O	1471	1475	node
O	1476	1486	dissection
O	1486	1487	.

O	1488	1489	A
O	1490	1500	randomized
O	1501	1506	study
O	1507	1511	with
O	1512	1517	large
O	1518	1527	effective
O	1528	1530	is
O	1531	1540	necessary
O	1540	1541	.
